Recognition follows news of BenchSci becoming the first non-US company to receive investment from Gradient Ventures, Google’s AI-focused venture fund

TORONTO – June 27, 2018 – BenchSci, an AI-powered search engine for biological products, has been ranked one of the top 25 up and coming technology companies on the Branham300, an annual list of the country’s top information and communications technology businesses.

“We’re thrilled to be recognized for our team’s hard work solving a profound problem with innovative machine learning technology,” said Liran Belenzon, CEO, BenchSci. “We appreciate the Branham Group for acknowledging our growth and efforts to accelerate biomedical discoveries by removing a major pain point for the world’s leading researchers.”

BenchSci’s ranking follows recent news of its Series A raise, in which it became the first medical technology and non-US company to receive funding from Gradient Ventures, Google's AI-focused venture fund.

BenchSci’s technology helps researchers find reliable antibodies faster and cheaper. Antibodies are essential to measuring the presence of proteins in drug discovery research. But there are more than 4 million to choose from, and many don’t work. BenchSci reads scientific papers the way a scientist would, decodes the antibody data within, and uses AI-assisted search to help researchers choose the optimal antibodies for their specific experiments.

The Branham300 is produced by the Branham Group Inc., a global information and communication technology industry analyst and strategic marketing company. It is the best-known and most widely referenced listing of the country’s top information and communications technologies companies. Its “Up and Coming” list ranks the top 25 companies that the Branham Group believes will be “big hits” soon.

About BenchSci

BenchSci accelerates biomedical discoveries. Researchers waste time and money on antibodies that don't work. This slows studies, destroys samples, and leaves patients waiting for treatments. Artificial intelligence can solve the problem, and we're building it. Our technology helps researchers find reliable antibodies 24x faster and 75% cheaper. BenchSci empowers researchers in 14 of the top 20 pharma companies and nearly 1,000 academic institutions globally. Academic researchers can sign up free at www.benchsci.com. Industry researchers can request a demo at www.benchsci.com/contact/.

About the Branham300

Branham Group Inc., a global Information and Communication Technology (ICT) industry analyst and strategic marketing company, celebrates the 25th anniversary of the Branham300 in 2018. The Branham300 is the best-known and most widely referenced listing of Canada's top ICT companies, ranked by revenue. The listing also tracks the top ICT multinationals operating in Canada, plus Up and Coming firms, those young Canadian companies Branham Group believes will be big hits soon. Branham Group’s ranking is unique in Canada because it tracks both publicly held and privately owned companies. It is the only comprehensive list to do so. The 2018 Up and Coming list is available at https://www.branham300.com/index.php?year=2018&listing=4

Media Contact:

Simon Smith

BenchSci

416-738-6058

simon@benchsci.com